Morepen Laboratories: Press Release – ' Morepen strengthens integrated CDMO capabilities with first U.S. ANDA submission
Morepen Laboratories (MOREPENLAB) filed a disclosure titled "Press Release – ' Morepen strengthens integrated CDMO capabilities with first U.S. The company is valued at about ₹6,596 crore.
What happened
Morepen Laboratories (MOREPENLAB) filed a disclosure with the exchanges on 28 September 2026 at 08:53 AM titled "Press Release – ' Morepen strengthens integrated CDMO capabilities with first U.S. ANDA submission".
Company snapshot
Morepen Laboratories is a small-cap company, with a market value of about ₹6,596 crore.
The stock last traded at ₹120.4, against a 52-week range of ₹33.05–₹126.8 (5.1% below the high).
Before this filing the shares had moved +24.5% over the month and +103.6% over three months. Average daily turnover over the last 20 sessions was about ₹225 crore.
Promoters held 35.65% at the end of Q1 FY27. Foreign institutions owned 1.46% and domestic institutions 1.28%.
What history shows
BCEIE's records show 2 previous similar filings from the company since May 2026.
After those filings, the stock fell 0.4% on average the next trading day and was up 2.6% on average after five days (2 filings with price data).
Market-wide, 32 similar filings with an impact score of 50 or more saw an average next-day move of +2.3%, with 72% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 7 Sept 2026 | — | +3.0% | +1.8% |
| 27 May 2026 | — | −3.9% | +3.4% |
In the news
Recent coverage elsewhere (links open the original publisher):
- Morepen Laboratories (MOREPENLAB) Share Price Falls 6.25% Today; Valuation and Sector Context in Focus
- We Ran A Stock Scan For Earnings Growth And Morepen Laboratories (NSE:MOREPENLAB) Passed With Ease
- Morepen Laboratories Submits First U.S. ANDA For Sitagliptin Tablets USP In Three Strengths
- Morepen Laboratories shares jump 5% after first US ANDA filing for diabetes drug; zoom 267% in 6 months
- Morepen Laboratories files its first US ANDA for sitagliptin tablets
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.